Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 129 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				C05004 NCT00257114


2.		A Study of Tanespimycin (KOS-953) in Patients With Relapsed-Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA200-003 KAG-302, NCT00514371

Last Modified: 5/14/2003 First Published: 11/1/2002


3.		Phase III Study of PS-341 in Patients With Refractory or Progressive Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MILLENNIUM-M34101-040 FHCRC-1747.00, NCI-G02-2128, NCT00049478

Last Modified: 4/30/2007 First Published: 11/24/2002


4.		Phase III Randomized Study of Bortezomib Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MILLENNIUM-M34101-039 FHCRC-1746.00, NCI-G02-2130, NCT00048230


5.		UARK 2003-33, Total Therapy III

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				UARK 2003-33 NCT00081939


6.		Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Other				UARK 2003-35 NCT00093028


7.		Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				DOXIL MMY 3001 NCT00103506


8.		Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Other				UARK 2005-01 NCT00111748


9.		VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				26866138-MMY-3002 NCT00111319


10.		Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				26866138-LYM-3001 NCT00312845

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute